290 related articles for article (PubMed ID: 31025722)
21. The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival.
Trinh VQ; Sirois J; Benzerdjeb N; Mansoori BK; Grosset AA; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Ladouceur M; Fradet Y; Saad F; Trudel D
Prostate; 2018 Jul; 78(10):697-706. PubMed ID: 29603326
[TBL] [Abstract][Full Text] [Related]
22. Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate.
Trinh VQ; Benzerdjeb N; Chagnon-Monarque S; Dionne N; Delouya G; Kougioumoutzakis A; Sirois J; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Zorn KC; Fradet Y; Saad F; Taussky D; Trudel D
Radiat Oncol; 2019 Apr; 14(1):60. PubMed ID: 31018850
[TBL] [Abstract][Full Text] [Related]
23. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
[TBL] [Abstract][Full Text] [Related]
24. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
[TBL] [Abstract][Full Text] [Related]
26. Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer.
Zhu S; Zhao JG; Chen JR; Liu ZH; Sun GX; Wang ZP; Ni YC; Dai JD; Shen PF; Zeng H
Asian J Androl; 2020; 22(5):519-525. PubMed ID: 31710002
[TBL] [Abstract][Full Text] [Related]
27. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
28. Addition of Cribriform and Intraductal Carcinoma Presence to Prostate Biopsy Reporting Strengthens Pretreatment Risk Stratification Using CAPRA and NCCN Tools.
Downes MR; Liu KN; Yu Y; Lajkosz K; Kroon LJ; Hollemans E; Fleshner N; Finelli A; van Leenders GJLH; Iczkowski KA; van der Kwast TH
Clin Genitourin Cancer; 2024 Feb; 22(1):47-55. PubMed ID: 37558528
[TBL] [Abstract][Full Text] [Related]
29. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.
Shah RB; Nguyen JK; Przybycin CG; Reynolds JP; Cox R; Myles J; Klein E; McKenney JK
Histopathology; 2019 Sep; 75(3):346-353. PubMed ID: 31012493
[TBL] [Abstract][Full Text] [Related]
30. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
[TBL] [Abstract][Full Text] [Related]
31. Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma.
Cohen RJ; Chan WC; Edgar SG; Robinson E; Dodd N; Hoscek S; Mundy IP
Br J Urol; 1998 Mar; 81(3):413-8. PubMed ID: 9523662
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.
Trudel D; Downes MR; Sykes J; Kron KJ; Trachtenberg J; van der Kwast TH
Eur J Cancer; 2014 Jun; 50(9):1610-6. PubMed ID: 24703897
[TBL] [Abstract][Full Text] [Related]
33. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
Seyrek N; Hollemans E; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Bangma CH; Rietbergen J; Roobol MJ; Schoots IG; van Leenders GJLH
Histopathology; 2022 Feb; 80(3):558-565. PubMed ID: 34706119
[TBL] [Abstract][Full Text] [Related]
34. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
35. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.
Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Roobol MJ; Helleman J; van Leenders GJLH
Histopathology; 2020 Apr; 76(5):755-762. PubMed ID: 31944367
[TBL] [Abstract][Full Text] [Related]
37. Comedonecrosis within conventional prostatic adenocarcinoma vs. intraductal carcinoma of the prostate: their clinical significance is not comparable.
Wang Y; Teramoto Y; Miyamoto H
Hum Pathol; 2023 Aug; 138():112-120. PubMed ID: 37364826
[TBL] [Abstract][Full Text] [Related]
38. Intraductal Carcinoma of the Prostate without High-Grade Invasive Adenocarcinoma: Report of Two Cases and Review of the Literature.
Ortiz-Rey JA; Bellas-Pereira A; San Miguel-Fraile P; Morellón-Baquera R; Domínguez-Arístegui P; González-Carreró Fojón J
Arch Esp Urol; 2022 Nov; 75(9):738-745. PubMed ID: 36472055
[TBL] [Abstract][Full Text] [Related]
39. The Clinical Impact of Comedonecrosis Within Intraductal Carcinoma of the Prostate.
Wang Y; Teramoto Y; Weisenthal SJ; Goto T; Miyamoto H
Arch Pathol Lab Med; 2023 Jan; 147(1):94-99. PubMed ID: 35472669
[TBL] [Abstract][Full Text] [Related]
40. Prostatic Ductal Adenocarcinoma Controlled for Tumor Grade, Stage, and Margin Status Does Not Independently Influence the Likelihood of Biochemical Recurrence in Localized Prostate Cancer After Radical Prostatectomy.
Kryvenko ON; Iakymenko OA; De Lima Guido LP; Bhattu AS; Merhe A; Mouzannar A; Briski LM; Oymagil I; Lugo I; Nemov I; Ritch CR; Kava BR; Punnen S; Jorda M; Parekh DJ; Gonzalgo ML
Arch Pathol Lab Med; 2022 Aug; 146(8):1012-1017. PubMed ID: 34739539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
